Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Serum Institute of India Ltd.

www.seruminstitute.com

Latest From Serum Institute of India Ltd.

Bharat Biotech Plans Coronavirus Vaccine

After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.

Commercial Vaccines

Codagenix-Serum Join Fray To Develop SARS-CoV-2 Vaccine

Codagenix, a company backed by Novartis, Merck and the Bill & Melinda Gates Foundation, has tied up with India’s Serum Institute to develop a vaccine against SARS-CoV-2, joining a heated race against the dreaded COVID-19 outbreak.

Research & Development Vaccines

Serum Institute Awaiting Gavi Push For $2 Pneumococcal Vaccine

Serum Institute hopes to hear by May from Gavi on whether it will consider the firm's $2 per dose pneumococcal conjugate vaccine for immunization programs across developing countries. Its 10-valent vaccine, versus GSK’s 11-valent and Pfizer’s 13-valent vaccines, is 30% cheaper.

Commercial Vaccines

Hilleman CEO Moving On, Hands Baton To Ex-Takeda Executive

Hilleman CEO Davinder Gill is leaving the global vaccine R&D organization after eight years at the helm and several mileposts. Incoming CEO Raman Rao takes charge from 1 February.

Commercial Appointments
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • India
  • Parent & Subsidiaries
  • Serum Institute of India Ltd.
  • Senior Management
  • Adar C Poonawalla, CEO
  • Contact Info
  • Serum Institute of India Ltd.
    Phone: (91) 202 699 3900
    212/2, Hadapsar, Off Soli Poonawalla Rd.
    Pune, 411028
    India
UsernamePublicRestriction

Register